Events | 2017.10.29
Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting
KING OF PRUSSIA, Pa., Oct. 29, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today presented data indicating that, at the approved dose of 60 IU/kg, HAEGARDA® reduced the median number of hereditary angioedema (HAE) attacks per month by 98 percent in subjects who had...
For more information, please visit
https://www.prnewswire.com/news-releases[...]entific-meeting-300545203.html
